Eversept Partners, LP Travere Therapeutics, Inc. Transaction History
Eversept Partners, LP
- $1.32 Billion
- Q2 2024
A detailed history of Eversept Partners, LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Eversept Partners, LP holds 1,091,165 shares of TVTX stock, worth $15.3 Million. This represents 0.68% of its overall portfolio holdings.
Number of Shares
1,091,165
Previous 955,618
14.18%
Holding current value
$15.3 Million
Previous $7.37 Million
21.75%
% of portfolio
0.68%
Previous 0.55%
Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.8MCall Options Held
137KPut Options Held
181K-
Black Rock Inc. New York, NY7.64MShares$107 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$105 Million0.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$103 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$92.6 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.48MShares$62.7 Million1.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $898M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...